Prof. Fangzhou Liu 刘方舟
Chief Physician, Professor
Department of Head and Neck Surgery, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis, surgery, and comprehensive treatment of head and neck tumors, including thyroid, laryngeal, salivary gland, nasal cavity, paranasal sinus, and oral cancers.
Dr. Liu holds a clinical medicine doctorate and completed postdoctoral work at Southeast University. A Chief Physician and Professor, Dr. Liu was a visiting scholar at Queen Mary Hospital (2010) and Memorial Sloan Kettering Cancer Center (2012), and conducted postdoctoral research at UMB, UC Berkeley, and Johns Hopkins Hospital (2014-2015). Dr. Liu has published over 20 papers and leads a National Natural Science Foundation project.
Professional roles
- Youth Committee Member, Jiangsu Provincial Otolaryngology-Head and Neck Surgery Academic Committee
- Committee Member, Nanjing Otolaryngology-Head and Neck Surgery Academic Committee
Name order: in Chinese the family name comes first (Liu Fangzhou). Papers usually list the name as Fangzhou Liu or Liu F.
Selected publications
21 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Discov Oncol, 2025 (senior author): The role of cellular heterogeneity in thyroid cancer: a multi-modal analysis approach with Mendelian randomization. PubMed 40770155
- Sci Rep, 2023 (senior author): Data mining on identifying diagnosis and prognosis biomarkers in head and neck squamous carcinoma. PubMed 37340028
- Front Cell Dev Biol, 2021 (senior author): Long Non-coding RNA RUNDC3A-AS1 Promotes Lung Metastasis of Thyroid Cancer via Targeting the miR-182-5p/ADAM9. PubMed 34046406
- Oral Oncol, 2021 (senior author): Development of a novel 7 immune-related genes prognostic model for oral cancer: A study based on TCGA database. PubMed 33220636
- Biomed Pharmacother, 2019 (first author): Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma. PubMed 30904818
- Int J Mol Med, 2018 (first author): miR-214 regulates papillary thyroid carcinoma cell proliferation and metastasis by targeting PSMD10. PubMed 30272290
- Turk J Biol, 2018 (first author): Effects of gold nanorods modified with antiepidermal growth factor receptor monoclonal antibody on laryngeal cancer cells. PubMed 30814876
- Biomed Pharmacother, 2017 (first author): MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway. PubMed 28987947
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion